This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2019:ehz486. https://doi.org/10.1093/eurheartj/ehz486.
Eurich DT, McAlister FA. Wrongfully accused: metformin use in heart failure. Expert Rev Cardiovasc Ther. 2011 Feb;9(2):147–50.
Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2011 Jan;4(1):53–8.
Roumie CL, Chipman J, Min JY, Hackstadt AJ, Hung AM, Greevy RA Jr, et al. Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function. JAMA. 2019 Sep;19:1–11. https://doi.org/10.1001/jama.2019.13206.
Chawla R, Madhu SV, Makkar BM, Ghosh S, Saboo B, Kalra S. RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. IJEM. 2020;24(1):1–122.
Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582–92. https://doi.org/10.1007/s00125-013-3039-1.
Conflict of interest
Authors are employees of Ipca Laboratories Limited which markets anti-diabetic drugs
Research involving human participants and/or animals
This manuscript did not involve participation of human volunteers or animal as this is a letter to the editor (comment on the guideline)
This manuscript did not require participation of humans and hence informed consent was not required as this is a letter to the editor (comment on the guideline)
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Pareek, A., Mehta, R.T. & Dharmadhikari, S. SGLT2 inhibitor/GLP-1 receptor agonists as first step monotherapy—evidence and implications. Int J Diabetes Dev Ctries (2020). https://doi.org/10.1007/s13410-020-00833-4